The New England Journal of Medicine is reporting on a limited compassionate use trial of the drug Remdesivir.
Doctors provided Remdesivir to 61 patients who were hospitalized with COVID-19. They received a 10-day course of Remdesivir between January 25, 2020 and March 7, 2020. Data from 8 could not be analyzed, and of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan.
The very limited study did a median 18-day followup. During that time, 36 patients showed improvement and 7 patients died.
The study notes that far more study is needed, specifically, ongoing randomized, placebo-controlled trials.
The study detail is online in The New England Journal of Medicine.
The publication has several articles about COVID-19 which they are making available to the public at no charge.
